Imunon, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
IMNN$0.77-12.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(14,495,028) | $(18,620,242) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 291,908 | 240,175 |
| Amortization of right-of-use assets | 406,992 | 477,941 |
| Realized losses, net, on investment securities | – | (61,983) |
| Stock-based compensation | 127,374 | 477,256 |
| Fair value of shares issued in exchange for services | 99,040 | – |
| Non-cash effect of reverse stock split | 704 | – |
| Realization of deferred income tax asset | – | 1.280.385 |
| Net changes in: | ||
| Advances, deposits, and other current assets | 193,507 | 408,859 |
| Accounts payable and accrued liabilities | (521,121) | (3,057,361) |
| Net cash used in operating activities | (13,896,624) | (18,854,970) |
| Cash flows from investing activities: | ||
| Purchases of investment securities | – | (57,174) |
| Proceeds from sale and maturity of investment securities | – | 9,915,448 |
| Purchases of property and equipment | (280,572) | (29,541) |
| Net cash (used in) provided by investing activities | (280,572) | 9,828,733 |
| Cash flows from financing activities: | ||
| Proceeds from sale of common stock equity, net of issuance costs | 13,628,070 | 9,060,438 |
| Proceeds from issuance of common stock upon exercise of warrants | 3,467,695 | – |
| Issuance costs of stock dividend | (10,277) | – |
| Net cash provided by financing activities | 17,085,488 | 9,060,438 |
| Net change in cash, cash equivalents | 2,908,292 | 34,201 |
| Cash and cash equivalents at the beginning of year | 5,872,767 | 5,838,566 |
| Cash and cash equivalents at the end of year | $8,781,059 | $5,872,767 |
| Supplemental Cash Flows Schedule | Years Ended December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Supplemental disclosure of cash flow information: | ||
| Non-Cash Investing and Financing Activities | ||
| Recognition of operating lease right-of-use asset and liability | $274,295 | – |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.